These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26765074)

  • 21. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada.
    McClure CA; MacSwain MA; Morrison H; Sanford CJ
    Vaccine; 2015 Apr; 33(15):1786-90. PubMed ID: 25731789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
    Moss JL; Reiter PL; Brewer NT
    Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain.
    Limia A; Pachón I
    Euro Surveill; 2011 May; 16(21):. PubMed ID: 21632017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
    Geier DA; Geier MR
    Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
    van der Maas NA; Kemmeren JM; de Melker HE
    Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global Delivery of Human Papillomavirus Vaccines.
    Wigle J; Fontenot HB; Zimet GD
    Pediatr Clin North Am; 2016 Feb; 63(1):81-95. PubMed ID: 26613690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK.
    Donegan K; Beau-Lejdstrom R; King B; Seabroke S; Thomson A; Bryan P
    Vaccine; 2013 Oct; 31(43):4961-7. PubMed ID: 24001935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study.
    Georgousakis M; Jayasinghe S; Brotherton J; Gilroy N; Chiu C; Macartney K
    Lancet Infect Dis; 2012 Aug; 12(8):627-34. PubMed ID: 22445354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunisation of adolescents in the UK.
    Kale AR; Snape MD
    Arch Dis Child; 2011 May; 96(5):492-5. PubMed ID: 21119024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The introduction of the human papillomavirus vaccine - key issues.
    Peate I
    Br J Nurs; 2009 Jan 22-Feb 11; 18(2):86-9. PubMed ID: 19270605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Socioeconomic predictors of human papillomavirus vaccination among girls in the Danish childhood immunization program.
    Slåttelid Schreiber SM; Juul KE; Dehlendorff C; Kjær SK
    J Adolesc Health; 2015 Apr; 56(4):402-7. PubMed ID: 25659994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
    Oliphant J; Perkins N
    N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.